What is she best known for?
The fields of study she is best known for:
Pamela J. Bjorkman mostly deals with Antibody, Virology, Binding site, Immunology and Major histocompatibility complex.
Her work carried out in the field of Antibody brings together such families of science as Ic50 values and Betacoronavirus.
Her studies in Virology integrate themes in fields like Epitope and Immunization.
Her Binding site research is multidisciplinary, incorporating perspectives in Antigen, Stereochemistry, Histocompatibility, Protein structure and Peptide.
Her Major histocompatibility complex study integrates concerns from other disciplines, such as Receptor and Cell biology.
Her study in Receptor is interdisciplinary in nature, drawing from both Immunoglobulin G, Plasma protein binding and Molecular biology.
Her most cited work include:
- Structure of the human class I histocompatibility antigen, HLA-A2. (3019 citations)
- Structure of the human class I histocompatibility antigen, HLA-A2. (3019 citations)
- T-cell antigen receptor genes and T-cell recognition. (2573 citations)
What are the main themes of her work throughout her whole career to date?
Pamela J. Bjorkman spends much of her time researching Antibody, Virology, Binding site, Neutralization and Epitope.
Pamela J. Bjorkman interconnects Virus, Molecular biology, Immune system and Antigen in the investigation of issues within Antibody.
Her work deals with themes such as T cell and T-cell receptor, which intersect with Antigen.
Her Virology study incorporates themes from Immunization, Monoclonal antibody, Glycoprotein and Severe acute respiratory syndrome coronavirus 2.
Her Binding site research incorporates elements of Protein structure, Receptor, Biophysics and Stereochemistry.
Her work carried out in the field of Neutralization brings together such families of science as Titer, Potency and Avidity.
She most often published in these fields:
- Antibody (46.32%)
- Virology (40.53%)
- Binding site (23.42%)
What were the highlights of her more recent work (between 2016-2021)?
- Antibody (46.32%)
- Virology (40.53%)
- Epitope (17.11%)
In recent papers she was focusing on the following fields of study:
Pamela J. Bjorkman focuses on Antibody, Virology, Epitope, Neutralization and Virus.
The study incorporates disciplines such as Heterologous, Binding site and Antigen in addition to Antibody.
Her Binding site research is multidisciplinary, incorporating perspectives in Biophysics and Trimer.
Her Virology research includes themes of Immunization, Immune system, Monoclonal antibody and Severe acute respiratory syndrome coronavirus 2.
Pamela J. Bjorkman has researched Epitope in several fields, including Lipid bilayer fusion, Polyclonal antibodies and Glycan.
Her Neutralization research is multidisciplinary, incorporating elements of Mutation, Titer, Avidity, Paratope and Coronavirus.
Between 2016 and 2021, her most popular works were:
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals. (1004 citations)
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. (555 citations)
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. (436 citations)
In her most recent research, the most cited papers focused on:
Her scientific interests lie mostly in Antibody, Virology, Epitope, Neutralization and Antigen.
Her studies link Immune system with Antibody.
Pamela J. Bjorkman interconnects Serology, Betacoronavirus, Glycoprotein and Polyclonal antibodies in the investigation of issues within Virology.
Her Neutralization research includes elements of Mutation, Titer, Immunization and Avidity.
As part of the same scientific family, Pamela J. Bjorkman usually focuses on Antigen, concentrating on Immunity and intersecting with Somatic hypermutation and Coronavirus.
Neutralizing antibody connects with themes related to Binding site in her study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
